Evaluation of a new combination: ceftriaxone-disodium edetate-sulbactam as a broad-spectrum option for multidrug-resistant bacterial infections.

Background: The presence of numerous antibiotic-resistance mechanisms in Gram-positive and Gram-negative bacteria is a global concern, which is further complicated by emergence of newer mechanisms in recent years. Few new compounds are in the production-pipeline that show potential for usage as anti...

Descripción completa

Detalles Bibliográficos
Publicado en:New Zealand Journal of Medical Laboratory Science Vol. 74; no. 1; pp. 22 - 27
Autores principales: Shahid, Mohd., Ahmed, Shariq, Iqbal, Zobair, Sami, Hiba, Singh, Anuradha
Formato: pictorial research tables/charts Journal Article
Publicado: New Zealand Institute of Medical Laboratory Science Apr2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142584174&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 142584174
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11710195
        H2G
      jtl: New Zealand Journal of Medical Laboratory Science
      issn: 11710195
      maglogo: N
    pubinfo:
      dt: Apr2020
      vid: 74
      iid: 1
      pid: 12822
      pub: New Zealand Institute of Medical Laboratory Science
    artinfo:
      ui:
        142584174
        142584174
        142584174
        142584174
      ppf: 22
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Evaluation of a new combination: ceftriaxone-disodium edetate-sulbactam as a broad-spectrum option for multidrug-resistant bacterial infections.
      aug:
        au:
          Shahid, Mohd.
          Ahmed, Shariq
          Iqbal, Zobair
          Sami, Hiba
          Singh, Anuradha
        affil: Department of Microbiology, Jawaharlal Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh, UP, India
      sug:
        subj:
          Bacterial Infections Drug Therapy
          Ceftriaxone Therapeutic Use
          Edetic Acid Therapeutic Use
          Penicillins Therapeutic Use
          Drug Combinations Pharmacodynamics
          Drug Resistance, Multiple Drug Effects
          Microbial Culture and Sensitivity Tests Methods
          Human
          Prospective Studies
          In Vitro Studies
          Gram-Positive Bacteria Metabolism
          Gram-Negative Bacteria Metabolism
          beta-Lactamases
          Carbapenems
          Colistin
          Methicillin
          Vancomycin
          Metabolic Networks and Pathways Drug Effects
          Academic Medical Centers
          India
          Treatment Outcomes Evaluation
      ab: Background: The presence of numerous antibiotic-resistance mechanisms in Gram-positive and Gram-negative bacteria is a global concern, which is further complicated by emergence of newer mechanisms in recent years. Few new compounds are in the production-pipeline that show potential for usage as antimicrobial agents. Antibiotic adjuvant ceftriaxone-disodium edetate-sulbactam, available under tradename Elores™, showed potential in this study by demonstrating antimicrobial activity against various multidrugresistant bacteria. Methods: In this prospective in-vitro study, we tested the antimicrobial activity of Elores™ against a battery of clinical Gram-positive and Gram-negative bacterial isolates, including antibiotic-susceptible and antibiotic-resistant bacteria such as ESBL-producing Enterobacterales (ESBLPE), carbapenem-resistant Enterobacterales (CRE), Enterobacterales showing colistin-resistance (ECR), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE). Results: Elores™ showed excellent activity against the tested Gram-positive and Gram-negative bacterial species, including some highly resistant species such as ESBL-producers, CRE, species resistant to colistin, MRSA and VRE. Elores™ was non-inferior to tigecycline in VRE isolates and non-inferior to colistin in Escherichia coli, Citrobacter species, Pseudomonas aeruginosa and Acinetobacter baumannii. However, in Klebsiella species the activity of Elores™ was notably better than colistin. Conclusions: In addition to activity against ESBL-producers and CRE, the activity of Elores™ against colistin-resistant Enterobacterales, MRSA and VRE showed promise, indicating its use as a potential candidate for empirical therapy due to its high activity against multidrug-resistant Gram-positive and Gram-negative bacteria.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N